Dr David Fuller has retired from the Board following almost six years service.

AdAlta Chairman, Paul MacLeman said:

“We sincerely thank David for his contribution over the past six years. His deep clinical expertise across multiple disease areas and across the region contributed significantly to the early clinical development of our fibrosis asset, AD-214, and the portfolio design for our “East to West” strategy.”